Tumor Biology

, Volume 36, Issue 6, pp 4397–4403 | Cite as

Prognostic value of soluble H7-B4 in pleural effusion associated with lung cancer

  • Chun-Hua Xu
  • Lan Cao
  • Xiu-Wei Zhang
  • Jun Yan
  • Li-Ke Yu
Research Article

Abstract

B7-H4, a member of the inhibitory B7 family, can restrain T cell proliferation, activation, and cytokine secretion and may be involved in immune evasion in cancer patients. This study aimed to evaluate the diagnostic and prognostic value of pleural effusion levels of soluble B7-H4 (sB7-H4) in lung cancer patients with malignant pleural effusion (MPE). Pleural effusion samples were collected from 98 lung cancer patients with malignant effusion and from 60 patients with nonmalignant pleural effusion. Pleural effusion concentrations of sB7-H4 were measured using sandwich enzyme-linked immunosorbent assay. Malignant effusion exhibited higher sB7-H4 levels than those in nonmalignant effusion (P < 0.01). Lung cancer patients with pleural effusion sB7-H4 levels below 35.8 ng/ml had a longer overall survival than those with higher levels (P < 0.05). By multivariate analysis, pleural effusion sB7-H4 was an independent prognostic factor in patients with MPE. In conclusion, measurement of sB7-H4 might be a useful diagnostic and prognostic value for MPE patients.

Keywords

Soluble B7-H4 Diagnosis Prognosis Lung cancer Pleural effusion 

Notes

Conflicts of interest

None

References

  1. 1.
    Kasahara K, Shibata K, Shintani H, Iwasa K, Sone T, et al. Randomized phase II trial of OK-432 in patients with malignant pleural effusion due to non-small cell lung cancer. Anticancer Res. 2006;26:1495–9.PubMedGoogle Scholar
  2. 2.
    Cheng D, Liang B, Li YH. Application of MMP-7 and MMP-10 in assisting the diagnosis of malignant pleural effusion. Asian Pac J Cancer Prev. 2012;13:505–9.CrossRefPubMedGoogle Scholar
  3. 3.
    Xu CH, Zhan P, Yu LK, Zhang XW. Diagnostic value of pleural interleukin 17 and carcinoembryonic antigen in lung cancer patients with malignant pleural effusions. Tumour Biol. 2014;35:1599–603.CrossRefPubMedGoogle Scholar
  4. 4.
    Hiraki A, Aoe K, Eda R, Maeda T, Murakami T, Sugi K, et al. Comparison of six biological markers for the diagnosis of tuberculous pleuritis. Chest. 2004;125:987–9.CrossRefPubMedGoogle Scholar
  5. 5.
    Heffner JE. Diagnosis and management of malignant pleural effusions. Respirology. 2008;13:5–20.CrossRefPubMedGoogle Scholar
  6. 6.
    Porcel JM, Vives M, Esquerda A, Salud A, Pérez B, et al. Use of a panel of tumor markers (carcinoembryonic antigen, cancer antigen 125, carbohydrate antigen 15-3, and cytokeratin 19 fragments) in pleural fluid for the differential diagnosis of benign and malignant effusions. Chest. 2004;126:1757–63.CrossRefPubMedGoogle Scholar
  7. 7.
    Su WC, Lai WW, Chen HH, Hsiue TR, Chen CW, et al. Combined intrapleural and intravenous chemotherapy, and pulmonary irradiation, for treatment of patients with lung cancer presenting with malignant pleural effusion. A pilot study. Oncology. 2003;64:18–24.CrossRefPubMedGoogle Scholar
  8. 8.
    Hsu IL, Su WC, Yan JJ, Chang JM, Lai WW. Angiogenetic biomarkers in non-small cell lung cancer with malignant pleural effusion: correlations with patient survival and pleural effusion control. Lung Cancer. 2009;65:371–6.CrossRefPubMedGoogle Scholar
  9. 9.
    Konishi J, Yamazaki K, Azuma M, Kinoshita I, Dosaka-Akita H, et al. B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression. Clin Cancer Res. 2004;10:5094–100.CrossRefPubMedGoogle Scholar
  10. 10.
    Simon I, Zhuo S, Corral L, Diamandis EP, Sarno MJ, et al. B7-h4 is a novel membrane-bound protein and a candidate serum and tissue biomarker for ovarian cancer. Cancer Res. 2006;66:1570–5.CrossRefPubMedGoogle Scholar
  11. 11.
    Zou W, Chen L. Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol. 2008;8:467–77.CrossRefPubMedGoogle Scholar
  12. 12.
    Quandt D, Fiedler E, Boettcher D, Marsch WC, Seliger B. B7-H4 expression in human melanoma: its association with patients’ survival and antitumor immune response. Clin Cancer Res. 2011;17:3100–11.CrossRefPubMedGoogle Scholar
  13. 13.
    Tringler B, Zhuo S, Pilkington G, Torkko KC, Singh M, et al. B7-h4 is highly expressed in ductal and lobular breast cancer. Clin Cancer Res. 2005;11:1842–8.CrossRefPubMedGoogle Scholar
  14. 14.
    Sun Y, Wang Y, Zhao J, Gu M, Giscombe R, et al. B7-H3 and B7-H4 expression in non-small-cell lung cancer. Lung Cancer. 2006;53:143–51.CrossRefPubMedGoogle Scholar
  15. 15.
    Tringler B, Liu W, Corral L, Torkko KC, Enomoto T, et al. B7-H4 overexpression in ovarian tumors. Gynecol Oncol. 2006;100:44–52.CrossRefPubMedGoogle Scholar
  16. 16.
    Krambeck AE, Thompson RH, Dong H, Lohse CM, Park ES, et al. B7-H4 expression in renal cell carcinoma and tumor vasculature: associations with cancer progression and survival. Proc Natl Acad Sci U S A. 2006;103:10391–6.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Zang X, Thompson RH, Al-Ahmadie HA, Serio AM, Reuter VE, et al. B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome. Proc Natl Acad Sci U S A. 2007;104:19458–63.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Chen LJ, Sun J, Wu HY, Zhou SM, Tan Y, et al. B7-H4 expression associates with cancer progression and predicts patient’s survival in human esophageal squamous cell carcinoma. Cancer Immunol Immunother. 2011;60:1047–55.CrossRefPubMedGoogle Scholar
  19. 19.
    Awadallah NS, Shroyer KR, Langer DA, Torkko KC, Chen YK, et al. Detection of B7-H4 and p53 in pancreatic cancer: potential role as a cytological diagnostic adjunct. Pancreas. 2008;36:200–6.CrossRefPubMedGoogle Scholar
  20. 20.
    Jiang J, Zhu Y, Wu C, Shen Y, Wei W, et al. Tumor expression of B7-H4 predicts poor survival of patients suffering from gastric cancer. Cancer Immunol Immunother. 2010;59:1707–14.CrossRefPubMedGoogle Scholar
  21. 21.
    Anderson GL, McIntosh M, Wu L, Barnett M, Goodman G, Thorpe JD, et al. Assessing lead time of selected ovarian cancer biomarkers: a nested case-control study. J Natl Cancer Inst. 2010;102:26–38.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Oikonomopoulou K, Li L, Zheng Y, Simon I, Wolfert RL, et al. Prediction of ovarian cancer prognosis and response to chemotherapy by a serum-based multiparametric biomarker panel. Br J Cancer. 2008;99:1103–13.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Simon I, Katsaros D, Rigault de la Longrai I, Massobrio M, Scorilas A, et al. B7-H4 is over-expressed in early-stage ovarian cancer and is independent of CA125 expression. Gynecol Oncol. 2007;106:334–41.CrossRefPubMedGoogle Scholar
  24. 24.
    Simon I, Liu Y, Krall KL, Urban N, Wolfert RL, et al. Evaluation of the novel serum markers B7-H4, Spondin 2, and DcR3 for diagnosis and early detection of ovarian cancer. Gynecol Oncol. 2007;106:112–8.CrossRefPubMedGoogle Scholar
  25. 25.
    Thompson RH, Zang X, Lohse CM, Leibovich BC, Slovin SF, et al. Serum-soluble B7x is elevated in renal cell carcinoma patients and is associated with advanced stage. Cancer Res. 2008;68:6054–8.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Arigami T, Uenosono Y, Hirata M, Hagihara T, Yanagita S, Ishigami S, et al. Expression of B7-H4 in blood of patients with gastric cancer predicts tumor progression and prognosis. J Surg Oncol. 2010;102:748–52.CrossRefPubMedGoogle Scholar
  27. 27.
    Kryczek I, Wei S, Zhu G, Myers L, Mottram P, Cheng P, et al. Relationship between B7-H4, regulatory T cells, and patient outcome in human ovarian carcinoma. Cancer Res. 2007;67:8900–5.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  • Chun-Hua Xu
    • 1
    • 2
  • Lan Cao
    • 2
  • Xiu-Wei Zhang
    • 3
  • Jun Yan
    • 4
  • Li-Ke Yu
    • 1
    • 2
  1. 1.Department of Respiratory MedicineNanjing Chest HospitalNanjingChina
  2. 2.Clinical Center of Nanjing Respiratory Diseases and ImagingNanjingChina
  3. 3.Department of Respiratory MedicineNanjing Jiangning HospitalNanjingChina
  4. 4.MOE Key Laboratory, Model Animal Research CenterNanjing UniversityNanjingChina

Personalised recommendations